Kimberly-Clark to Acquire Kenvue in $48.7 Billion Deal

November 3, 2025 By usmanthotti business 2 min read

Kimberly-Clark to Acquire Kenvue in $48.7 Billion Deal

Kimberly-Clark Corporation has announced a definitive agreement to acquire Kenvue Inc., the maker of Tylenol, in a cash and stock transaction valued at approximately $48.7 billion. This strategic move aims to create a leading consumer health goods company with a diverse portfolio of well-known brands.

Details of the Acquisition

Under the terms of the agreement, Kenvue shareholders will receive $3.50 per share in cash and 0.14625 shares of Kimberly-Clark stock for each Kenvue share held. Based on Kimberly-Clark’s closing price on October 31, 2025, this equates to $21.01 per Kenvue share. Post-transaction, Kimberly-Clark shareholders will own about 54% of the combined entity, while Kenvue shareholders will hold approximately 46%.

Combined Company Portfolio and Financial Outlook

The merger will bring together iconic brands such as Kimberly-Clark’s Huggies, Kleenex, and Kotex with Kenvue’s Tylenol, Neutrogena, and Band-Aid. The combined company is projected to generate annual net revenues of approximately $32 billion. Additionally, the companies have identified about $1.9 billion in cost savings expected within the first three years after the deal’s closure.

Leadership and Headquarters

Mike Hsu, Chairman and CEO of Kimberly-Clark, will lead the merged organization, which will maintain its headquarters in Irving, Texas. Hsu emphasized the shared commitment to innovation and consumer care, stating that the combined company will serve billions of consumers across every stage of life.

Regulatory Approval and Expected Closing

The transaction is subject to regulatory approvals and is anticipated to close in the second half of 2026. Both companies are optimistic about the merger’s potential to enhance their market position and deliver value to shareholders.

Market Reaction

Following the announcement, Kenvue’s stock experienced a significant increase, rising approximately 20% in premarket trading. Conversely, Kimberly-Clark’s shares saw a decline, reflecting mixed investor sentiment regarding the acquisition’s impact on the company’s financials and strategic direction.